Abstract
Omalizumab (Xolair; Genentech/Novartis/ Tanox/Sankyo), a monoclonal antibody that binds selectively to the key allergic-reaction mediator immunoglobulin E, was approved by the FDA in June 2003 for the treatment of moderate to severe allergic asthma in patients whose symptoms are inadequately controlled by inhaled corticosteroids. Could omalizumab drive expansion of the asthma market and so reach blockbuster status?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tailored therapy for severe asthma
Multidisciplinary Respiratory Medicine Open Access 16 January 2015
-
Genetics of asthma: a molecular biologist perspective
Clinical and Molecular Allergy Open Access 06 May 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lundbäck, B. Epidemiology of rhinitis and asthma. Clin. Exp. Allergy 28, S2 3–10 (1998).
Chang, T. W. The pharmacological basis of anti-IgE therapy. Nature Biotechnol. 18, 157–162 (2000).
Busse, W. W. & Lemanske, R. F. Asthma. N. Engl. J. Med. 344, 350–362 (2001).
Presta, L. G. et al. Humanization of an antibody directed against IgE. J. Immunol. 151, 2623–2632 (1993).
MacGlashan, D. W. Jr et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 158, 1438–1445 (1997).
FDA Drug Approvals List [online], (cited 28 Jan 2004), <http://www.fda.gov/cder/foi/label/2003/omalgen062003LB.pdf> (2003).
National Institute of Allergy and Infectious Disease. Fact Sheet #9: Asthma and its Environmental Triggers: Scientists Take a Practical New Look at a Familiar Illness [online], (cited 28 Jan 2004) <http://www.niehs.nih.gov/oc/factsheets/asthma.htm>
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ames, S., Gleeson, C. & Kirkpatrick, P. Omalizumab. Nat Rev Drug Discov 3, 199–200 (2004). https://doi.org/10.1038/nrd1334
Issue Date:
DOI: https://doi.org/10.1038/nrd1334
This article is cited by
-
Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management
Clinical Reviews in Allergy & Immunology (2021)
-
Tailored therapy for severe asthma
Multidisciplinary Respiratory Medicine (2015)
-
Genetics of asthma: a molecular biologist perspective
Clinical and Molecular Allergy (2009)